JP2008509166A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008509166A5 JP2008509166A5 JP2007525077A JP2007525077A JP2008509166A5 JP 2008509166 A5 JP2008509166 A5 JP 2008509166A5 JP 2007525077 A JP2007525077 A JP 2007525077A JP 2007525077 A JP2007525077 A JP 2007525077A JP 2008509166 A5 JP2008509166 A5 JP 2008509166A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- aralkyl
- hydrogen
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC1(*C1)C(C(*)N(*)C(C(Cc1ccccc1)N(*)C(C(*)N(*)C([C@](CCc1ccccc1)N(*)C(CN1CCOCC1)=O)=O)=O)=O)=O Chemical compound CC1(*C1)C(C(*)N(*)C(C(Cc1ccccc1)N(*)C(C(*)N(*)C([C@](CCc1ccccc1)N(*)C(CN1CCOCC1)=O)=O)=O)=O)=O 0.000 description 3
- FUBFVNSFQLMWCN-ULIWIOEXSA-N CC(C)CC(C([C@]1(C)OC1)=O)NC([C@H](C)NC([C@H](CC(C)C)NC([C@H](CCc1ccccc1)NC(CC(C)CC(C)N1CCOCC1)=O)=O)=O)=O Chemical compound CC(C)CC(C([C@]1(C)OC1)=O)NC([C@H](C)NC([C@H](CC(C)C)NC([C@H](CCc1ccccc1)NC(CC(C)CC(C)N1CCOCC1)=O)=O)=O)=O FUBFVNSFQLMWCN-ULIWIOEXSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59940104P | 2004-08-06 | 2004-08-06 | |
| US60/599,401 | 2004-08-06 | ||
| US61000104P | 2004-09-14 | 2004-09-14 | |
| US60/610,001 | 2004-09-14 | ||
| US11/106,879 | 2005-04-14 | ||
| US11/106,879 US7232818B2 (en) | 2004-04-15 | 2005-04-14 | Compounds for enzyme inhibition |
| PCT/US2005/028246 WO2006017842A1 (en) | 2004-08-06 | 2005-08-08 | Compounds for proteasome enzyme inhibition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011047047A Division JP5394423B2 (ja) | 2004-08-06 | 2011-03-04 | プロテアソーム酵素阻害のための化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008509166A JP2008509166A (ja) | 2008-03-27 |
| JP2008509166A5 true JP2008509166A5 (https=) | 2008-10-02 |
| JP4743720B2 JP4743720B2 (ja) | 2011-08-10 |
Family
ID=35502451
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007525077A Expired - Lifetime JP4743720B2 (ja) | 2004-08-06 | 2005-08-08 | プロテアソーム酵素阻害のための化合物 |
| JP2011047047A Expired - Lifetime JP5394423B2 (ja) | 2004-08-06 | 2011-03-04 | プロテアソーム酵素阻害のための化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011047047A Expired - Lifetime JP5394423B2 (ja) | 2004-08-06 | 2011-03-04 | プロテアソーム酵素阻害のための化合物 |
Country Status (24)
| Country | Link |
|---|---|
| US (12) | US7232818B2 (https=) |
| EP (4) | EP2266999B1 (https=) |
| JP (2) | JP4743720B2 (https=) |
| KR (3) | KR20130080064A (https=) |
| CN (1) | CN102286070B (https=) |
| AT (1) | ATE496062T1 (https=) |
| AU (1) | AU2005271232B2 (https=) |
| BR (2) | BRPI0514102B8 (https=) |
| CA (1) | CA2589765C (https=) |
| CY (3) | CY1116771T1 (https=) |
| DE (1) | DE602005026019D1 (https=) |
| DK (2) | DK1781688T3 (https=) |
| ES (2) | ES2525248T3 (https=) |
| FR (1) | FR16C0017I2 (https=) |
| HU (2) | HUE038005T2 (https=) |
| IL (3) | IL181127A (https=) |
| LT (2) | LT3101026T (https=) |
| LU (1) | LU93015I2 (https=) |
| NO (2) | NO341015B1 (https=) |
| PL (2) | PL1781688T3 (https=) |
| PT (2) | PT3101026T (https=) |
| SG (2) | SG10201701794UA (https=) |
| SI (2) | SI1781688T1 (https=) |
| WO (1) | WO2006017842A1 (https=) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7176232B2 (en) | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
| US7232818B2 (en) * | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
| US8198270B2 (en) * | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
| WO2005105827A2 (en) | 2004-04-15 | 2005-11-10 | Proteolix, Inc. | Compounds for proteasome enzyme inhibition |
| US8088741B2 (en) * | 2004-05-10 | 2012-01-03 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
| US20050256324A1 (en) * | 2004-05-10 | 2005-11-17 | Proteolix, Inc. | Synthesis of amino acid keto-epoxides |
| EP1830838B1 (en) | 2004-12-03 | 2012-10-03 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating neoplastic diseases |
| HUE027850T2 (en) * | 2004-12-07 | 2016-11-28 | Onyx Therapeutics Inc | Preparation for proteasome inhibition |
| RU2453556C2 (ru) | 2005-11-09 | 2012-06-20 | Протеоликс, Инк. | Соединения для ингибирования фермента |
| RU2450016C2 (ru) | 2006-06-19 | 2012-05-10 | Протеоликс, Инк. | Пептидные эпоксикетоны для ингибирования протеасомы |
| EP2040694A2 (en) * | 2006-07-14 | 2009-04-01 | VIB vzw | Use of ppar-alpha agonists to treat skeletal muscle wasting disorders |
| US7642369B2 (en) * | 2006-09-12 | 2010-01-05 | University Of Kentucky Research Foundation | Epoxyketone-based immunoproteasome inhibitors |
| AU2013203566B2 (en) * | 2007-10-04 | 2016-10-13 | Onyx Therapeutics, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| AU2016231532B2 (en) * | 2007-10-04 | 2018-05-10 | Onyx Therapeutics, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| KR20170040374A (ko) * | 2007-10-04 | 2017-04-12 | 오닉스 세라퓨틱스, 인크. | 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성 |
| US8394816B2 (en) * | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
| EP2088205A1 (en) | 2008-02-11 | 2009-08-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | PSMB10: A diagnosis marker and therapeutic target of chronic rejection. |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| WO2009140287A1 (en) * | 2008-05-12 | 2009-11-19 | Nereus Pharmaceuticals, Inc. | Salinosporamide derivatives as proteasome inhibitors |
| AU2009308516B2 (en) | 2008-10-21 | 2016-08-25 | Onyx Therapeutics, Inc. | Combination therapy with peptide epoxyketones |
| AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
| US20110009332A1 (en) * | 2009-07-09 | 2011-01-13 | Southwest Research Institute | Therapeutic Treatment Of Wounds |
| GB0914883D0 (en) | 2009-08-26 | 2009-09-30 | Univ Belfast | Compound |
| JP5919196B2 (ja) | 2009-11-13 | 2016-05-18 | オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 転移抑制のためのペプチドエポキシケトンの使用 |
| CA2791651C (en) | 2010-03-01 | 2019-08-20 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
| NZ602872A (en) | 2010-04-07 | 2014-05-30 | Onyx Therapeutics Inc | Crystalline peptide epoxyketone immunoproteasome inhibitor |
| US9126997B1 (en) | 2010-09-07 | 2015-09-08 | Northwestern University | Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma |
| WO2012135528A2 (en) | 2011-03-29 | 2012-10-04 | Texas Tech University System | Galectin-3c combination therapy for human cancer |
| WO2013009923A1 (en) * | 2011-07-13 | 2013-01-17 | Creighton University | Methods of promoting neuron growth |
| CA2855368A1 (en) | 2011-11-11 | 2013-05-16 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
| CN104039328B (zh) | 2011-11-11 | 2018-10-09 | 米伦纽姆医药公司 | 对蛋白酶体抑制剂的反应的生物标记 |
| JP6215235B2 (ja) | 2012-01-24 | 2017-10-18 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 癌の治療方法 |
| DK3702374T3 (da) | 2012-02-15 | 2022-06-27 | Cydex Pharmaceuticals Inc | Fremsgangsmåde til fremstilling for cyclodextrin-derivater |
| KR20200130748A (ko) | 2012-05-08 | 2020-11-19 | 오닉스 세라퓨틱스, 인크. | 펩티드 프로테아좀 억제제 제제화를 위한 사이클로덱스트린 복합체화 방법 |
| JP2015524394A (ja) | 2012-07-09 | 2015-08-24 | オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ |
| WO2014015027A1 (en) | 2012-07-18 | 2014-01-23 | Onyx Therapeutics, Inc. | Liposomal compositions of epoxyketone-based proteasome inhibitors |
| CA2881986A1 (en) * | 2012-08-21 | 2014-02-27 | Fluorinov Pharma Inc. | Fluorinated epoxyketone-based tetrapeptide compounds and uses thereof as proteasome inhibitors |
| WO2014066274A1 (en) | 2012-10-22 | 2014-05-01 | Cydex Pharmaceuticals, Inc. | Alkylated cyclodextrin compositions and processes for preparing and using the same |
| JP6279065B2 (ja) | 2013-03-13 | 2018-02-14 | サノフイ | 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物 |
| ES2687368T3 (es) | 2013-03-14 | 2018-10-24 | Onyx Therapeutics, Inc. | Inhibidores de proteasa de epoxi cetona dipeptídica y tripeptídica |
| AR095426A1 (es) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
| MX372671B (es) | 2013-07-19 | 2020-04-23 | Onyx Therapeutics Inc | Inhibidores de proteasoma de epoxicetona peptídica en combinacion con inhibidores de cinasa pim para el tratamiento de canceres. |
| CN103360348B (zh) * | 2013-07-25 | 2015-06-24 | 苏州鹏旭医药科技有限公司 | 一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法 |
| CN105518019A (zh) * | 2013-09-06 | 2016-04-20 | 桑多斯股份公司 | 肽环氧基酮的合成 |
| US20160194354A1 (en) * | 2013-09-06 | 2016-07-07 | Sandoz Ag | Stereoselective synthesis of diols and triols by mannich reaction and their use in the synthesis of carfilzomib |
| WO2015121769A1 (en) | 2014-02-13 | 2015-08-20 | Ranbaxy Laboratories Limited | Process for the preparation of methyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phenylalaninate |
| CN103864889B (zh) * | 2014-04-04 | 2017-01-11 | 重庆泰濠制药有限公司 | 环氧酮化合物、其制备方法及卡非佐米的制备方法 |
| JP6914188B2 (ja) | 2014-08-22 | 2021-08-04 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | 分画アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法 |
| WO2016046843A1 (en) | 2014-09-24 | 2016-03-31 | Biophore India Pharmaceuticals Pvt. Ltd. | Process for the preparation of (s)-4-methyl-n-((s)-1-(((s)-4-methyl-1-((r)-2-methyloxiran-2-yl)-1-oxo pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide |
| US20160115198A1 (en) | 2014-10-27 | 2016-04-28 | Apicore Us Llc | Methods of making carfilzomib and intermediates thereof |
| CN104402973A (zh) * | 2014-11-24 | 2015-03-11 | 重庆泰濠制药有限公司 | 一种卡非佐米无定型晶的制备方法 |
| EP3227312B1 (en) | 2014-12-02 | 2019-05-29 | Fresenius Kabi Oncology Limited | A process for purification of carfilzomib |
| EP3240575A4 (en) | 2014-12-31 | 2018-07-25 | Dr. Reddy's Laboratories Ltd. | Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib |
| WO2016170544A1 (en) * | 2015-04-22 | 2016-10-27 | Msn Laboratories Private Limited | Process for the preparation of (2s)-n-((s)-1-((s)-4-methyl-1-((r)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((s)-2-(2-morpholino acetamido)-4-phenylbutanamido)-4-methylpentanamide |
| WO2016185450A1 (en) | 2015-05-21 | 2016-11-24 | Laurus Labs Private Limited | An improved processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof |
| CN106317188A (zh) * | 2015-06-18 | 2017-01-11 | 重庆医药工业研究院有限责任公司 | 一种制备卡非佐米无定型物的方法 |
| WO2017032487A1 (en) | 2015-08-27 | 2017-03-02 | Technische Universität München | Proteasome inhibitor comprising a signal-emitting moiety |
| WO2017098532A1 (en) | 2015-12-11 | 2017-06-15 | Mylan Laboratories Limited | Crystalline and amorphous forms of carfilzomib |
| TWI636052B (zh) * | 2015-12-31 | 2018-09-21 | 中化合成生技股份有限公司 | 無定形卡非佐米(i)的製備方法 |
| US11306107B2 (en) | 2016-02-25 | 2022-04-19 | Amgen Inc. | Compounds that inhibit MCL-1 protein |
| TWI759301B (zh) * | 2016-05-24 | 2022-04-01 | 美商安美基公司 | 聚乙二醇化卡非佐米化合物 |
| WO2018024645A1 (en) | 2016-08-02 | 2018-02-08 | Synthon B.V. | Process for making carfilzomib |
| PH12019500232B1 (en) | 2016-08-05 | 2023-11-15 | Amgen Inc | Synthesis of (s)-2-amino-4-methyl-1-((r)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof |
| CN109689635A (zh) | 2016-09-14 | 2019-04-26 | 费森尤斯卡比肿瘤学有限公司 | 一种用于纯化卡非佐米中间体的方法 |
| EP3512602B1 (en) | 2016-09-16 | 2024-03-27 | HSF Pharmaceuticals | Inhibitors of heat shock factors (hsf) and uses thereof |
| EP3330260A1 (en) | 2016-12-01 | 2018-06-06 | Enantia, S.L. | Process for the preparation of an intermediate for the synthesis of i.a. carfilzomib |
| JP2020533382A (ja) | 2017-09-14 | 2020-11-19 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 癌の組合せ治療 |
| JP2021503441A (ja) | 2017-11-16 | 2021-02-12 | アムジエン・インコーポレーテツド | Ｐｅｇ化されたカルフィルゾミブ化合物の安定組成物 |
| CN117051096A (zh) * | 2017-12-08 | 2023-11-14 | 神经Gx有限责任公司 | 用于阿尔茨海默病的同步化细胞周期基因表达测试及相关治疗方法 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| CA3043103C (en) * | 2017-12-30 | 2021-02-09 | Unity Biotechnology | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer |
| US10689416B2 (en) | 2017-12-30 | 2020-06-23 | Unity Biotechnology, Inc. | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer |
| US20210276952A1 (en) * | 2018-06-22 | 2021-09-09 | Ucl Business Ltd | Novel compounds |
| WO2021072212A1 (en) * | 2019-10-11 | 2021-04-15 | Mayo Foundation For Medical Education And Research | Proteasome inhibitors |
| EP4139289A1 (en) * | 2020-04-21 | 2023-03-01 | University of Rochester | Inhibitors of human epididymus protein 4 |
| US20250295771A1 (en) | 2022-05-11 | 2025-09-25 | Celgene Corporation | Methods and uses related to t cell therapy and production of same |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| TW202430548A (zh) | 2022-09-29 | 2024-08-01 | 日商武田藥品工業股份有限公司 | Ｃｄ３８結合融合蛋白組合療法 |
| WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
| CN116768972A (zh) * | 2023-06-25 | 2023-09-19 | 重庆药友制药有限责任公司 | 一种卡非佐米中间体的制备方法 |
| WO2025035020A2 (en) | 2023-08-09 | 2025-02-13 | Amgen Inc. | Methods of using carfilzomib |
| EP4685151A1 (en) | 2024-07-24 | 2026-01-28 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Proteasome inhibitor |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US569748A (en) | 1896-10-20 | Henry edmunds | ||
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5071957A (en) | 1989-08-04 | 1991-12-10 | Bristol-Myers Company | Antibiotic BU-4061T |
| US4990448A (en) | 1989-08-04 | 1991-02-05 | Bristol-Myers Company | Bu-4061T |
| US5340736A (en) | 1991-05-13 | 1994-08-23 | The President & Fellows Of Harvard College | ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting |
| AU4499697A (en) | 1996-09-13 | 1998-04-02 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
| US6099851A (en) * | 1998-06-02 | 2000-08-08 | Weisman; Kenneth M. | Therapeutic uses of leuprolide acetate |
| US6902721B1 (en) | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
| US6462019B1 (en) | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
| US6838436B1 (en) | 1998-07-10 | 2005-01-04 | Osteoscreen Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
| US6204257B1 (en) | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
| US6492333B1 (en) | 1999-04-09 | 2002-12-10 | Osteoscreen, Inc. | Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors |
| US6831099B1 (en) | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
| EP1477180A1 (en) | 1999-10-20 | 2004-11-17 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone and hair growth |
| JP4412586B2 (ja) | 2002-01-08 | 2010-02-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | エポネマイシンおよびエポキソマイシン類似物およびそれらの用途 |
| WO2005105827A2 (en) * | 2004-04-15 | 2005-11-10 | Proteolix, Inc. | Compounds for proteasome enzyme inhibition |
| US7232818B2 (en) * | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
| US20050256324A1 (en) | 2004-05-10 | 2005-11-17 | Proteolix, Inc. | Synthesis of amino acid keto-epoxides |
| US8088741B2 (en) | 2004-05-10 | 2012-01-03 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
-
2005
- 2005-04-14 US US11/106,879 patent/US7232818B2/en not_active Expired - Lifetime
- 2005-08-08 ES ES10012498.1T patent/ES2525248T3/es not_active Expired - Lifetime
- 2005-08-08 AT AT05784484T patent/ATE496062T1/de active
- 2005-08-08 DK DK05784484.7T patent/DK1781688T3/da active
- 2005-08-08 ES ES16166492.5T patent/ES2674277T3/es not_active Expired - Lifetime
- 2005-08-08 JP JP2007525077A patent/JP4743720B2/ja not_active Expired - Lifetime
- 2005-08-08 KR KR1020137016063A patent/KR20130080064A/ko not_active Withdrawn
- 2005-08-08 EP EP10012498.1A patent/EP2266999B1/en not_active Expired - Lifetime
- 2005-08-08 AU AU2005271232A patent/AU2005271232B2/en active Active
- 2005-08-08 PL PL05784484T patent/PL1781688T3/pl unknown
- 2005-08-08 LT LTEP16166492.5T patent/LT3101026T/lt unknown
- 2005-08-08 BR BRPI0514102A patent/BRPI0514102B8/pt active IP Right Grant
- 2005-08-08 SG SG10201701794UA patent/SG10201701794UA/en unknown
- 2005-08-08 US US11/199,899 patent/US7417042B2/en active Active
- 2005-08-08 WO PCT/US2005/028246 patent/WO2006017842A1/en not_active Ceased
- 2005-08-08 KR KR1020127030701A patent/KR101544258B1/ko not_active Expired - Lifetime
- 2005-08-08 PT PT161664925T patent/PT3101026T/pt unknown
- 2005-08-08 SI SI200531264T patent/SI1781688T1/sl unknown
- 2005-08-08 PL PL16166492T patent/PL3101026T3/pl unknown
- 2005-08-08 HU HUE16166492A patent/HUE038005T2/hu unknown
- 2005-08-08 PT PT05784484T patent/PT1781688E/pt unknown
- 2005-08-08 BR BR122020008634A patent/BR122020008634B8/pt active IP Right Grant
- 2005-08-08 EP EP16166492.5A patent/EP3101026B1/en not_active Expired - Lifetime
- 2005-08-08 EP EP05784484A patent/EP1781688B1/en not_active Expired - Lifetime
- 2005-08-08 CN CN201110145272.7A patent/CN102286070B/zh not_active Expired - Lifetime
- 2005-08-08 SG SG200905204-4A patent/SG155187A1/en unknown
- 2005-08-08 SI SI200532211T patent/SI3101026T1/en unknown
- 2005-08-08 CA CA2589765A patent/CA2589765C/en not_active Expired - Lifetime
- 2005-08-08 DK DK16166492.5T patent/DK3101026T3/en active
- 2005-08-08 DE DE602005026019T patent/DE602005026019D1/de not_active Expired - Lifetime
- 2005-08-08 EP EP10012497.3A patent/EP2270026B1/en not_active Expired - Lifetime
- 2005-08-08 KR KR1020077003533A patent/KR101354280B1/ko not_active Expired - Lifetime
- 2005-08-08 IL IL181127A patent/IL181127A/en active Protection Beyond IP Right Term
-
2007
- 2007-02-20 NO NO20070965A patent/NO341015B1/no unknown
- 2007-04-11 US US11/786,217 patent/US7491704B2/en not_active Expired - Lifetime
-
2011
- 2011-03-04 JP JP2011047047A patent/JP5394423B2/ja not_active Expired - Lifetime
- 2011-04-04 CY CY20111100347T patent/CY1116771T1/el unknown
-
2012
- 2012-08-22 IL IL221572A patent/IL221572B/en active IP Right Grant
-
2014
- 2014-08-06 US US14/452,844 patent/US20140342977A1/en not_active Abandoned
-
2015
- 2015-08-26 US US14/835,876 patent/US20150361134A1/en not_active Abandoned
-
2016
- 2016-04-05 HU HUS1600014C patent/HUS1600014I1/hu unknown
- 2016-04-06 LU LU93015C patent/LU93015I2/xx unknown
- 2016-04-08 US US15/094,088 patent/US20160222057A1/en not_active Abandoned
- 2016-04-12 LT LTPA2016010C patent/LTC1781688I2/lt unknown
- 2016-04-22 CY CY2016009C patent/CY2016009I1/el unknown
- 2016-05-12 FR FR16C0017C patent/FR16C0017I2/fr active Active
-
2017
- 2017-03-14 NO NO20170381A patent/NO344397B1/no unknown
-
2018
- 2018-02-13 US US15/895,120 patent/US20180170962A1/en not_active Abandoned
- 2018-06-20 CY CY181100642T patent/CY1120677T1/el unknown
- 2018-09-20 IL IL261892A patent/IL261892B/en active IP Right Grant
-
2019
- 2019-03-13 US US16/351,669 patent/US20190211058A1/en not_active Abandoned
- 2019-10-31 US US16/669,601 patent/US20200071356A1/en not_active Abandoned
-
2020
- 2020-06-26 US US16/912,806 patent/US20200325172A1/en not_active Abandoned
-
2021
- 2021-02-08 US US17/169,990 patent/US20210179663A1/en not_active Abandoned
-
2022
- 2022-04-29 US US17/733,077 patent/US20220267372A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008509166A5 (https=) | ||
| JP2008522981A5 (https=) | ||
| JP2008501637A5 (https=) | ||
| JP2009504763A5 (https=) | ||
| RU2006143664A (ru) | Соединения для ингибирования ферментов | |
| JP2020507589A5 (https=) | ||
| JP2015518055A5 (https=) | ||
| JP2014503525A5 (https=) | ||
| RU2011103741A (ru) | Композиции и способы лечения заболевания сетчатки | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| JP2007016035A5 (https=) | ||
| JP2013010792A5 (https=) | ||
| JP2015535839A5 (https=) | ||
| JP2009504764A5 (https=) | ||
| JP2011513305A5 (https=) | ||
| JPH11193282A5 (https=) | ||
| JP2014500265A5 (https=) | ||
| JP2013501047A5 (https=) | ||
| JP2011513410A5 (https=) | ||
| RU2009118254A (ru) | Фенилацетамиды в качестве ингибиторов протеинкиназ | |
| JP2008505157A5 (https=) | ||
| JP2013518036A5 (https=) | ||
| JP2006509842A5 (https=) | ||
| WO2011089529A4 (en) | Salicylate fatty acid derivatives | |
| RU2015137298A (ru) | Ингибиторы тирозинкиназы брутона |